Mumbai : The Indian Pharmaceuticals Association (IPA) has found new President and Vice President appointees in Nilesh Gupta ,Director,Lupin , and Glenn Saldanha ,Chairman and Managing Director Glenn Pharmaceuticals ltd respectiebly . The IPA, initially formed by eight national companies in November 1999, now has 20 research based national pharmaceutical companies as part of its body.
The eight member’s constitute Dr Reddy’s Laboratories, Sun Pharmaceuticals Industries, Lupin, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Cadila Healthcare, Alkem Laboratories, Alembic, Mylan Labs, Micro Labs, Cadila Pharmaceuticals, Natco Pharma, Cipla, Panacea Biotec, Wockhardt, Intas Pharmaceuticals, Unichem Laboratories, Ipca Laboratories, USV and JB Chemicals& Pharmaceuticals reports the Indian White Paper.
Together, the IPA members account for nearly 85 per cent of the private sector investment in pharmaceutical research and development, contributing 60 per cent of the country’s exports of drugs and pharmaceuticals; servicing over 40 per cent of the domestic market, and accounting for 43 per cent of total sales of essential medicines.
The IPA, a credible alternative capable of looking after all stakeholders in the pharmaceutical industry, grasping the emerging scenario, has worked with the government steering the local industry to newer heights
Formed with the objectives of partnering the government for evolution of a patent regime and meet the TRIPs obligations as well as serve national interest; Its role being to engage the government in constructive dialogue on price management from price control for the benefit of the consumer; Its role also includes collaborating with the government in progressively upgrading regulatory provisions, procedures and standards to suit the country’s requirements; as well assisting the government agencies in carrying out a campaign against spurious drugs, a menace to the society.
Nilesh Gupta is managing director of Lupin Limited. A chemical engineer from the University Department of Chemical Technology, Mumbai, and an MBA from the Wharton School, USA, he is responsible for transforming Lupin’s research programmes, strengthening the company’s global manufacturing operations and quality functions and is a key part of the top team formulating and executing the core strategy that has helped Lupin emerge as a global generic and specialty pharmaceutical major.
Glenn Saldanha is chairman & managing director of Glenmark Pharmaceuticals Limited. He holds a bachelor’s degree in pharmacy from Mumbai University and an MBA from Leonard Stern School of Business, New York University. Prior to Glenmark, he worked with Eli Lily, USA and PricewaterhouseCoopers, USA.
In 2014 he was conferred with Best CEO: Pharma & Healthcare (mid-sized companies) by Business Today. Also in the same year he was ranked among the ‘Top 50 CEOs in India’ by Entrepreneur Magazine. He was also conferred the ‘Swiss Ambassador’s Award for Exceptional Innovation’ in 2012 by Embassy of Switzerland and was among the Top 30 Youth Icons of India (2012) by The Hindustan Times.